BTRC-4017A
- Generic Name
- BTRC-4017A
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Phase 1
Active, not recruiting
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT03448042
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, Rhône, France
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸START MADRID_Hospital Universiario Fundacion Jimenez Diaz, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath